US Patent 7514416 Interferon alpha and antisense K-ras RNA combination gene therapy

Methods of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding a human IFN-alpha and operably linked to a promoter, and the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence, wherein the antisense K-ras nucleotide sequence is operably linked to a promoter, and the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppress growth of pancreatic tumor or cancer cells in the mammal.